Mulling Bernanke's ...
Health Care: Drugs
Celldex Therapeutics Inc. (CLDX: NASDAQ)
$15.31 -0.09 | -0.58%
06/19/13 - 01:50 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 24.90M | 11.90M | 21.29M | 57.00M |
| Receivables | 44.00K | 170.00K | 324.00K | 544.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 85.11M | 54.68M | 62.95M | 83.98M |
| Property, Plant & Equipment, Gross | 19.53M | 19.46M | 19.61M | 18.21M |
| Accumulated Depreciation & Depletion | 12.32M | 10.37M | 8.77M | 6.72M |
| Property, Plant & Equipment, Net | 7.20M | 9.09M | 10.83M | 11.49M |
| Intangibles | 23.83M | 24.92M | 26.84M | 29.98M |
| Other Non-Current Assets | 424.00K | 329.00K | 363.00K | 5.96M |
| Total Non-Current Assets | 40.43M | 43.31M | 47.00M | 56.39M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 125.54M | 97.99M | 109.94M | 140.36M |
| Accounts Payable | 745.00K | 935.00K | 931.00K | 1.44M |
| Short Term Debt | 5.59M | 6.14M | 13.52M | 2.16M |
| Other Current Liabilities | 388.00K | 219.00K | 818.00K | 0.00 |
| Total Current Liabilities | 17.68M | 14.30M | 20.21M | 14.41M |
| Long Term Debt | 5.75M | 9.01M | 8.89M | 11.68M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 6.34M | 5.97M | 5.59M | 40.51M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 12.08M | 14.97M | 14.48M | 52.19M |
| Total Liabilities | 29.77M | 29.27M | 34.69M | 66.60M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 95.77M | 68.72M | 75.26M | 73.77M |
| Common Par | 64.00K | 44.00K | 32.00K | 32.00K |
| Additional Paid In Capital | 357.09M | 271.03M | 232.68M | 228.86M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -264.13M | -205.01M | -160.21M | -157.67M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 2.74M | 2.65M | 2.75M | 2.55M |
| Total Capitalization | 101.52M | 77.73M | 84.14M | 85.45M |
| Total Equity | 95.77M | 68.72M | 75.26M | 73.77M |
| Total Liabilities & Stock Equity | 125.54M | 97.99M | 109.94M | 140.36M |
| Total Common Shares Outstanding | 64.36M | 44.21M | 32.06M | 31.69M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 57.71M | 39.50M | 31.87M | 19.82M |
| Diluted Weighted Shares Outstanding | 57.71M | 39.50M | 31.87M | 19.82M |
| Number of Employees | 106 | 103 | 94 | 90 |
| Number of Part-Time Employees | 6 | 0 | 6 | 3 |
Portfolios with CLDX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- Userbio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
Latest CLDX Headlines from TheStreet
- 5 Stocks Poised for Breakouts 04.19.13 | 02:04 pm
- Celldex Presents CDX-1127 In Vitro Human Data Consistent With Strong Potency And Safety Profile At AACR 2013 04.08.13 | 01:04 pm
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Celldex Reports Fourth Quarter And Fiscal 2012 Financial Results 03.07.13 | 08:03 am
- Celldex Therapeutics To Report Fourth Quarter And Fiscal 2012 Financial Results And Host Corporate 2013 Strategic Outlook Call 02.28.13 | 08:02 am
- Positive Data From Celldex's Phase 1 Study Of CDX-301 Support Initiation Of Pilot Study In Hematopoietic Stem Cell Transplantation 02.14.13 | 08:02 am
- Celldex Therapeutics Announces Upcoming Presentation At Leerink Swann Global Healthcare Conference 2013 02.11.13 | 04:02 pm
- Celldex Announces Upcoming Oral Presentation On CDX-301 At The American Society For Blood And Marrow Transplantation 2013 BMT Tandem Meetings 02.11.13 | 09:02 am
- Celldex Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares 02.08.13 | 08:02 am
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
Press Releases for CLDX
- Celldex Therapeutics’ CDX-301 Safely Mobilizes Hematopoietic Cells In Phase 1 Study; Future Development Planned - Business Wire 12.11.12 | 08:12 am
- Final Data From Celldex Therapeutic’s CDX-011 Phase 2 Study In Metastatic Breast Cancer Supports Overall Survival Benefit In Patients With High GPNMB Expression - Business Wire 12.08.12 | 08:12 am
- Celldex Therapeutics Announces Upcoming Presentation At Oppenheimer Healthcare Conference - Business Wire 12.07.12 | 11:12 am
- Celldex Therapeutics Announces Upcoming Data Presentations On CDX-1127 And CDX-011 - Business Wire 12.04.12 | 10:12 am
- Celldex Therapeutics Announces Upcoming Presentation At The Deutsche Bank 2012 DbAccess BioFEST - Business Wire 11.30.12 | 08:11 am
- Celldex Therapeutics Announces Positive Three-Year Survival Data For Rindopepimut Phase 2 Clinical Program - Business Wire 11.15.12 | 05:11 pm
- Celldex Therapeutics Announces Upcoming Presentation At Lazard Capital Markets Healthcare Conference - Business Wire 11.09.12 | 09:11 am
- Celldex Announces Upcoming Data Presentation At The American Society Of Hematology 54th Annual Meeting And Exposition - Business Wire 11.05.12 | 04:11 pm
- Celldex Announces Upcoming Data Presentations At The Society For Neuro-Oncology 17th Annual Scientific Meeting And Education Day - Business Wire 11.05.12 | 07:11 am
- Celldex Reports Third Quarter 2012 Financial Results - Business Wire 11.01.12 | 08:11 am
Partner Headlines for CLDX
- 5 Stocks To Watch For Gains Next Week - Seeking Alpha 06.07.13 | 07:06 pm
- Cramer's Mad Money - 11 Things To Watch In The Week Ahead (5/31/13) - Seeking Alpha 06.02.13 | 07:06 am
- Pre-Market Earnings Report for March 7, 2013 : CNQ, KR, BTE, SFD, NAV, JW/A, FGP, CIEN, EPL, PRIM, CMN, CLDX - NASDAQ 03.06.13 | 09:03 pm
- Anything Can Happen This Year For Celldex - Seeking Alpha 02.18.13 | 09:02 am
- Pre-Market Most Active for Feb 6, 2013 : ELN, QQQ, BAC, BBRY, ZNGA, NOK, GSK, VMED, KB, SNY, ARMH, CLDX - NASDAQ 02.06.13 | 01:02 pm
- Pre-Market Most Active for Dec 11, 2012 : AIG, BAC, HTZ, NOK, FB, HCA, GSK, SIRI, AAPL, URBN, QQQ, CLDX - NASDAQ 12.11.12 | 01:12 pm
- UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex Therapeutics - Benzinga 11.02.12 | 09:11 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Pre-Market Earnings Report for August 10, 2012 : BAM, JCP, HAR, CYD, HSFT, CLDX, HZNP, SCR, XIN, URRE, HSKA, DLGC - NASDAQ 08.09.12 | 08:08 pm
- Even In Clinical Studies, Big Potential For MRI-Guided Procedures - Seeking Alpha 06.28.12 | 09:06 am
